ALPHA
Hormones & TRT · 21 min · 4,018 words

Oral Testosterone Undecanoate vs Injections: What the FDA Labels Actually Say

Most comparisons of Jatenzo, Tlando and Kyzatrex against cypionate injections lead with a blood pressure boxed warning that no longer exists. The current labels tell a more useful story, and it does not favour the pills on cost.

Oral Testosterone Undecanoate vs Injections: What the FDA Labels Actually Say

The case for oral testosterone is simple: no needles, no vials, no glute injections every week or two. The case against it is usually made by pointing at the box on the label. That argument is out of date. In 2025 the FDA reworked the labelling for every testosterone product, and the black-box blood pressure warning that set the oral capsules apart came off all three of them. It also came off a weekly injection most people forget had the same box.

What is left is a comparison on the things that actually differ: levels, blood pressure, daily effort and cost. We read the current FDA labels for all three oral undecanoate products, the Xyosted enanthate autoinjector and Pfizer's Depo-Testosterone, then the trial the FDA used to rewrite them.

Recommended

Starting from

$59/mo

Free consultation

MangoRx logo

4.2 AHF · 3.9 Trustpilot

ODT delivery + L-Arginine/Oxytocin combo formulation is genuinely differentiated ED tech — faster absorption, novel combo profile, mid-tier pricing.

Get Started Free

The boxed warning is gone, and it was never an oral-only problem

When Jatenzo was approved in 2019 it carried a boxed warning for blood pressure increases, and Tlando and Kyzatrex followed with the same box. It is still the first thing most people say about oral testosterone.

On 28 February 2025 the FDA told every testosterone sponsor to add the results of TRAVERSE to their labels, to remove boxed-warning language about an increased risk of adverse cardiovascular outcomes, and to carry blood pressure information class-wide [6]. The agency's reasoning was that the required ambulatory blood pressure monitoring studies had "confirmed an increase in blood pressure with use of all testosterone products, class-wide" [6]. Products with a completed ABPM study got their own numbers; products without one got a new general warning.

The current labels show the result. Jatenzo's "Recent Major Changes" block lists the blood pressure boxed warning as removed, along with the old contraindication for "age-related hypogonadism" [1]. Tlando and Kyzatrex both show the same removal dated 07/2025 [2][3]. None of the three carries a boxed warning on its current DailyMed label.

Here is the part that gets lost. Xyosted, the weekly subcutaneous testosterone enanthate autoinjector, had a blood pressure boxed warning of its own, and its label shows it removed in 03/2025 [4]. The box was never about swallowing testosterone. It was about which manufacturers had been made to run 24-hour blood pressure studies — and the newer branded products, oral and injectable alike, were the ones that had.

The product that never ran one is the one most men are actually on. Depo-Testosterone, Pfizer's cypionate and the reference for the generic vials most TRT clinics dispense, now carries the general class statement: testosterone "can increase blood pressure which can increase cardiovascular (CV) risk over time," with periodic monitoring advised and use not recommended in uncontrolled hypertension [5]. It has no product-specific ABPM figure, because no such study appears in its label. The cypionate label also still carries older language noting that "some studies, but not all" reported increased MACE with testosterone [5].

So the honest version of the blood pressure argument runs the opposite way to the usual one. The oral products have measured blood pressure effects you can read. The injection most men use has an assumed one, with no number attached.

What the measured numbers are

All of these are 24-hour ambulatory readings, which are far more reliable than a single cuff reading in a clinic. All are changes from the patient's own baseline in single-arm studies with no placebo group, which matters, and we come back to it.

Product (route)Study lengthMean systolic / diastolic changeMen already on BP medication
Jatenzo (oral TU)~4 months, n=135+4.9 / +2.5 mm Hg+5.4 / +3.2 mm Hg
Tlando (oral TU)~16 weeks, n=123+4.3 / +1.4 mm Hg+4.8 / +1.6 mm Hg
Kyzatrex (oral TU)4 and 6 months, n=151+1.7 / +0.6, then +1.8 / +0.6 mm Hg+3.4 / +0.7, then +3.1 / +1.0 mm Hg
Xyosted (subcutaneous enanthate)12 weeks, n=62+3.9 / +1.5 mm Hg+3.9 / +1.3 mm Hg
Depo-Testosterone (IM cypionate)No ABPM study in labelNot reportedNot reported

Sources: Jatenzo [1], Tlando [2], Kyzatrex [3], Xyosted [4], Depo-Testosterone [5].

Two details deserve more attention than the headline figures. Jatenzo's label states that "average blood pressures had not plateaued at the end of the trial" [1], so the four-month number may be an underestimate of where it settles. During that same study, 7.2% of Jatenzo patients either started blood pressure medication or had their regimen increased [1]. On Xyosted, the comparable figure was 10% over a year [4]. That is the real-world consequence of a few millimetres of mercury: one man in ten to fourteen ending up on more blood pressure medication.

Kyzatrex has the smallest numbers on the table, and it would be easy to declare it the winner. We would not. These are separate single-arm studies in different populations — in Tlando's ABPM study, 48% of men had a history of hypertension and 70% were obese [2] — and the label for each product is explicit that rates from different trials "cannot be directly compared." In Kyzatrex's study, men already on antihypertensives rose by 3.4 mm Hg systolic at four months while men without hypertension rose by 0.7 mm Hg, with a confidence interval crossing zero [3]. The signal sits in the men who already have high blood pressure, which is consistent with every other product here.

What TRAVERSE settled, and what it did not

The trial that drove the relabel is TRAVERSE, published in the New England Journal of Medicine in 2023 [7]. It randomised 5,246 men aged 45 to 80 with existing cardiovascular disease or high cardiovascular risk, two fasting testosterone readings below 300 ng/dL and symptoms of hypogonadism, to testosterone or placebo. Mean treatment ran 21.7 months and mean follow-up 33 months.

The primary endpoint — cardiovascular death, non-fatal heart attack or non-fatal stroke — occurred in 7.0% of the testosterone group and 7.3% of the placebo group (hazard ratio 0.96, 95% CI 0.78 to 1.17), which met the trial's non-inferiority test [7]. Systolic pressure over 36 months differed between groups by just 1.5 mm Hg [1]. The trial also found a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism with testosterone [7], which the labels now reflect in their venous thromboembolism sections (1.7% vs 1.2% for VTE overall) [2].

That is a genuinely reassuring result for a high-risk population, and it is why the box came off. But TRAVERSE tested a daily 1.62% transdermal gel [7] — not a capsule, not an injection. Every label for every route now quotes it because it is the only outcomes trial anyone has run. That is a reasonable regulatory call, but it is not evidence that oral undecanoate or intramuscular cypionate shares a gel's cardiovascular profile, and the oral products raise blood pressure by more than TRAVERSE's 1.5 mm Hg in their own studies.

The useful reading for a man choosing between the two: blood pressure is a reason to measure, not a reason to pick one route over the other. If you already take blood pressure medication, budget for a home cuff and an earlier review whichever route you choose. If your pressure is uncontrolled, every one of these labels says the product is not recommended until it is [1][3][5].

Levels: what "in range" meant in each pivotal trial

Each product was approved on the same kind of endpoint: the share of men whose 24-hour average testosterone (Cavg) landed in a predefined normal range at the end of the study. Here is how they did.

  • Jatenzo: 87% of 166 men in range after about four months of titrated dosing; 83% kept their peak (Cmax) at or below 1,500 ng/dL, and 3% peaked above 2,500 ng/dL [1].
  • Tlando: 80% of 95 men in range (95% CI 72% to 88%) after 24 days, at a fixed dose with no titration; 82% kept their peak at or below 1,620 ng/dL, and none exceeded 2,700 ng/dL [2].
  • Kyzatrex: 88% of 139 men in range at day 90 (95% CI 82% to 93%); 88% kept their peak at or below 1,200 ng/dL, and none exceeded 2,000 ng/dL [3].
  • Xyosted: 90% of 150 men in range at week 12 across the weekly dosing interval, with no patients above 1,500 ng/dL [4].

On paper the weekly subcutaneous injection edges out every oral product on both measures. That is worth stating plainly, because "oral gives smoother levels than injections" is one of the most repeated claims in this space. It is true compared to a 200 mg cypionate shot every two weeks. The Xyosted data says it is not true compared to a small weekly dose.

Several caveats apply, and they are not minor. The ranges differ between products — Kyzatrex used a plasma range of 222 to 800 ng/dL [3], Tlando used 300 to 1,080 ng/dL [2], Xyosted 300 to 1,100 ng/dL [4] — so an 88% here and an 87% there are not measuring the same target. Tlando's study ran less than four weeks. All four studies were open-label with no comparator arm. And cypionate, the injection most men actually use, has no comparable pivotal study in its label at all. Its label gives an intramuscular half-life of about eight days and a dosing range of 50 to 400 mg every two to four weeks [5], which on the longer intervals is exactly the peak-and-trough pattern people mean when they complain about injections. A 2025 review of the three oral products describes injectable esters as producing "supraphysiologic peaks and subtherapeutic troughs" [9]. That is a fair description of the label regimen; it is a much weaker description of how most TRT clinics now dose cypionate, which is in smaller weekly or twice-weekly amounts.

So the oral products clearly beat a fortnightly cypionate protocol on smoothness. Compared to a well-run weekly injection, the levels data does not give them an edge.

Dosing burden: two meals a day vs one needle a week

This is where the choice usually gets made, and it is where the labels are most specific.

Every oral product must be taken twice a day with food. The food requirement is not a suggestion. Taken fasting, Tlando's peak concentration fell by about 65% and total exposure by 38% compared to a high-fat meal [2]. Kyzatrex exposure rose by 37%, 87% and 94% with breakfasts of 16%, 33% and 45% fat compared to fasting [3]. Jatenzo was less sensitive across normal breakfasts, but a 15 g fat breakfast still delivered 25% less testosterone than a 30 g fat breakfast [1]. If you skip breakfast, grab a black coffee, or eat a low-fat meal on a cut, your morning dose is partly wasted.

Pill counts add up. At its fixed dose, Tlando is two 112.5 mg capsules twice a day — four capsules daily, roughly 1,460 a year [2]. Jatenzo starts at one 237 mg capsule twice daily and can go to two 198 mg capsules twice daily at the top dose [1]. Kyzatrex starts at 200 mg twice daily and ranges from a single 100 mg morning dose to 400 mg twice daily [3]. Compare that to Xyosted at one 75 mg subcutaneous autoinjector a week into the abdomen [4], or generic cypionate at one intramuscular shot every one to two weeks in typical clinic practice.

Monitoring is fiddlier on the pills. Each oral product has its own blood-draw timing, and they are not interchangeable:

ProductWhen to drawTarget or rule
Jatenzo6 hours after the morning dose, at least 7 days after starting or changing dose425–970 ng/dL; titrate between 158 mg and 396 mg twice daily [1]
Kyzatrex3 to 5 hours after the morning dose, 7 days after starting or changing dose460–971 ng/dL; titrate between 100 mg daily and 400 mg twice daily [3]
Tlando8 to 9 hours after the morning dose, 3 to 4 weeks after starting300–1,080 ng/dL to continue; below or above, discontinue [2]
XyostedTrough, 7 days after the last dose, after 6 weeks350–650 ng/dL; adjust by 25 mg [4]

Tlando's rule deserves attention. It has no titration. If your level is out of range at the check, the label says stop, not adjust [2]. That makes it the simplest oral product to take and the least forgiving if it does not suit you.

Both Tlando and Kyzatrex state that they are not substitutable with other oral testosterone undecanoate products [2][3]. If your pharmacy or insurer pushes you from one brand to another, that is a new start with new labs, not a like-for-like swap.

Our view: for a man who already eats two regular meals a day and dreads needles, the pills are a legitimate choice. For a man who skips breakfast, travels a lot or forgets doses, a weekly injection is the better choice by a distance — fourteen doses a week, each dependent on a meal, is fourteen chances to miss. If you go the injection route, our guides to cypionate vs enanthate and injection sites cover the practical side.

If you want to compare who prescribes which route before deciding, our TRT provider comparison breaks down modality, price and lab inclusion side by side.

The rest of the trade: hematocrit, liver, fertility and cost

Hematocrit

Rising red blood cell mass is the side effect most likely to interrupt testosterone therapy. All three oral labels require hematocrit monitoring roughly every three months [1][3], or every three months in the first year and then every six months for Tlando [2].

The label figures look like a clear win for oral: "hematocrit increased" in 4.8% of Jatenzo patients over about four months [1] and 4.3% of Tlando patients over about four months [2], against 14.0% of Xyosted patients over a year [4]. On Xyosted, 4.2% of 283 men reached a hematocrit of 55% or more within a year, and mean hematocrit rose by 5.4 percentage points at one year [4]. We would read those comparisons cautiously, because a four-month study and a one-year study are not catching the same thing, and Jatenzo's own label notes that its hematocrit rises appeared in the second half of the study [1].

The broader literature does point the same way. A 2018 review of testosterone-induced erythrocytosis concluded that short-acting injectable formulations carry the highest incidence of erythrocytosis compared with other routes [8]. That is the strongest evidence-based argument for oral undecanoate over cypionate, and it rests on cross-formulation comparison rather than any trial pitting the two against each other.

Liver

This is the old fear about oral testosterone, and it does not apply here. The hepatotoxicity associated with older oral androgens came from 17-alpha-alkylated compounds such as methyltestosterone. Kyzatrex's label states directly that it "is not a 17-alpha-alkyl androgen and is not known to cause hepatic adverse effects" [3]. Jatenzo's and Tlando's labels carry the standard class paragraph on alkylated androgens, which also notes that long-term intramuscular testosterone enanthate has produced hepatic adenomas [1][2]. Liver risk is not a reason to choose injections over modern oral undecanoate.

Other label differences

Tlando's label alone requires a prolactin check before starting and again three to four months in, after 6.3% of men in its 24-day study showed raised prolactin [2]. Jatenzo listed a decrease in HDL cholesterol in 3.0% of patients [1]. Every oral label asks for periodic lipid monitoring [1][2][3].

Fertility

There is no fertility advantage to the pills. All three oral labels warn that exogenous testosterone may cause azoospermia [1][2][3]. If preserving sperm production matters to you in the next few years, neither route is the right starting point; that is a separate conversation, usually about enclomiphene or hCG. Hims prescribes enclomiphene as a non-testosterone option for that reason.

Cost and access

This is the injection's strongest point, and it is not close.

Generic testosterone cypionate is made by multiple manufacturers; DailyMed lists cypionate labels from several companies alongside Pfizer's Depo-Testosterone. In telehealth, that translates into all-inclusive TRT memberships built around it. In our own provider data, DudeMeds lists commercial-grade cypionate with labs and consultations from $77 a month, MangoRx lists injectable TRT at $99 a month including labs, PeterMD prices medication from $79 to $139 a month with separate baseline labs, and Roman runs TRT at $135 a month. Prices move; check them before you sign up, and see our full TRT cost breakdown for gel and pellet comparisons.

The oral products sit on a different scale. A 2025 comparative review describes Jatenzo as historically the highest-priced of the three, with insurers frequently requiring prior authorisation or step therapy [9]. The same review puts average wholesale prices for a 30-day supply of Tlando and Kyzatrex "in the several hundred-dollar range," notes that copay assistance exists for both, and describes Kyzatrex as available self-pay at roughly $150 without prior authorisation [9]. "Step therapy" in practice often means your insurer wants you to try and fail on a cheaper route first — usually injections or gel.

Access is the narrower bottleneck. Most telehealth TRT services prescribe cypionate, cream or enclomiphene rather than an FDA-approved oral undecanoate. MangoRx is one of the few in our data that lists Kyzatrex alongside injectable cypionate, which makes it the obvious place to start if you want to try oral without changing provider later. Maximus lists an oral testosterone option in its TRT range; ask specifically whether it is an FDA-approved undecanoate product before you assume it is the same thing.

Is the pill worth the premium? For a cash payer it can cost several times an all-inclusive injectable membership, for a product the trials do not show produces better levels than a weekly injection. The premium buys needle-free convenience and, plausibly, a lower erythrocytosis risk. For some men that is worth it. For most, it is not.

What hasn't been studied, and who should choose which

Start with the gaps, because they matter more than any single number above.

No randomised trial has compared oral testosterone undecanoate head to head with injectable testosterone. The 2025 review of the three oral products says so in as many words, and adds that none has been compared in a large randomised trial with transdermal formulations either [9]. Every pivotal trial behind the orals was open-label, single-arm and short — 24 days for Tlando, about four months for Jatenzo and six months for Kyzatrex [1][2][3]. The review also notes that Tlando and Kyzatrex did not use validated symptom questionnaires [9]. We know these capsules move a number on a blood test. We have very little controlled data on whether men feel better on them than on an injection.

No cardiovascular outcomes trial has used either route. TRAVERSE used gel [7]. The labels borrow it because it is all there is.

Cypionate's blood pressure effect has never been measured the way the orals' was. The most-prescribed testosterone in America carries a class warning with no product-specific number [5]. That does not mean it is worse; it means the comparison everyone makes is between a measured risk and an unmeasured one.

And the labelled population is narrower than the market. Every product here, oral and injectable, carries the same limitation of use: safety and efficacy in men with "age-related hypogonadism" have not been established [1][2][3][4][5]. The FDA retained that language in 2025 even as it dropped the cardiovascular box [6]. Most men in their 40s and 50s on TRT fall into exactly that group, which is worth knowing before anyone tells you either route is "FDA-approved for low T."

Given all of that, here is where we land.

Injections win for most men. Weekly cypionate or Xyosted gets as many men into range as any capsule, costs a fraction of the price, needs one action a week instead of fourteen, and does not depend on breakfast. If you are price-sensitive or forget pills, this is clearly the better choice.

Oral undecanoate wins for a specific man: needle-averse, eats two regular meals a day, has normal or well-controlled blood pressure, has run into hematocrit problems on injections, and has insurance coverage or is comfortable paying cash. For him it is a real option, and the 2025 relabel removed the strongest objection to it.

Nobody should choose either because of the blood pressure box. It is gone from both oral and injectable branded labels, and the measured increases are small for most men and larger for those already on blood pressure medication. Measure it either way.

If you would rather start with a clinician in the room, in-person clinics can draw the timed labs the oral products need on site. In Florida, TRT Nation in Tampa is one option. In Illinois, Chicagoland Men's Health in Chicago focuses specifically on low testosterone. Our hormone optimisation hub covers the full range of options beyond these two routes.

Frequently asked questions

Do Jatenzo, Tlando and Kyzatrex still have a black box warning?

No. All three current FDA labels list the blood pressure boxed warning as removed, following the FDA's February 2025 class-wide labelling changes [1][2][3][6]. Each still carries a standard warning that it can raise blood pressure and is not recommended in men with uncontrolled hypertension.

Is oral testosterone safer for the liver than older testosterone pills?

Yes. Older oral androgens such as methyltestosterone were 17-alpha-alkylated, which is what caused liver damage. Testosterone undecanoate is not; Kyzatrex's label states it is not a 17-alpha-alkyl androgen and is not known to cause hepatic adverse effects [3].

Does oral testosterone raise blood pressure more than injections?

The labels cannot tell you. Mean 24-hour systolic increases ranged from 1.7 mm Hg (Kyzatrex) to 4.9 mm Hg (Jatenzo) for oral products and 3.9 mm Hg for the Xyosted injection, all in separate single-arm studies [1][3][4]. Generic cypionate has no comparable measurement in its label [5]. No trial has compared the routes directly.

Why do I have to take oral testosterone with food?

Absorption depends heavily on dietary fat. Taken fasting, Tlando reached about 65% lower peak levels and 38% lower total exposure than with a high-fat meal [2], and Kyzatrex exposure nearly doubled with a 45% fat breakfast compared to fasting [3].

Can I switch between Jatenzo, Tlando and Kyzatrex?

Not directly. Tlando's and Kyzatrex's labels both state they are not substitutable with other oral testosterone undecanoate products [2][3], and each uses different doses, blood-draw timing and target ranges. A switch means restarting the titration and repeating labs.

Does oral testosterone protect fertility better than injections?

No. All three oral labels warn that exogenous testosterone can cause azoospermia [1][2][3]. Men who want to preserve fertility should discuss non-testosterone options such as enclomiphene or hCG with a clinician.

Sources

A

Alpha Health Finder Editorial Team

Editorial Team

The Alpha Health Finder editorial team researches and writes evidence-based men's health content. Articles are grounded in cited primary sources and reviewed against a fixed editorial standard before publication. We are a research and directory team — not your prescribing clinicians.

More from Alpha →

Looking for an online provider?

Find a qualified online provider — compare options vetted and reviewed by Alpha Health Finder.

Alpha Journal

One email a week. The research, not the hype.

What we published this week, what we changed our minds about, and what it means if you are on a protocol.

No spam, no selling your address. Unsubscribe in one click.

Take the next step

Featured Online Provider

MangoRx logo
4.2

AHF editorial rating

3.9 on Trustpilot, 5 reviews

ODT delivery + L-Arginine/Oxytocin combo formulation is genuinely differentiated ED tech — faster absorption, novel combo profile, mid-tier pricing.

Also treats

Erectile Dysfunction Treatment · Injectable Testosterone Therapy · Oral Testosterone (Kyzatrex) · Enclomiphene Therapy · Hair Loss Treatment · GLP-1 Weight Loss

Starting at
$59/mo
Consultation
Free
Coverage
Most States
Turnaround
Same-Day Shipping
Continue reading
How Long to Fast Before a Testosterone Blood Test
Hormones & TRT · 11 min

How Long to Fast Before a Testosterone Blood Test

Fast overnight, nothing but water, and get your blood drawn between 7 and 10 a.m. A meal can push testosterone down by a quarter within an hour, and a single low reading should always be repeated before anyone calls it low T.

Nov 19, 2026
Share
Ashwagandha for Stressed Men: What the Trials Show on Anxiety, Cortisol and Testosterone
Hormones & TRT · 10 min

Ashwagandha for Stressed Men: What the Trials Show on Anxiety, Cortisol and Testosterone

Ashwagandha is sold to men as a testosterone booster, but its best evidence is for stress and anxiety. The trials are small, short and mostly paid for by extract makers. The testosterone effect is real and small.

Nov 18, 2026
Share
Gonadorelin vs hCG After TRT: What the Evidence Shows
Hormones & TRT · 16 min

Gonadorelin vs hCG After TRT: What the Evidence Shows

hCG has a randomised trial showing it keeps testicular testosterone near normal on TRT and a case series showing men stayed fertile on it. Gonadorelin, the drug many clinics swapped in after 2020, has no published trial in men on TRT at all.

Nov 17, 2026
Share
TRT vs Enclomiphene for Fertility
Hormones & TRT · 15 min

TRT vs. Enclomiphene for Fertility: Which Hormone Strategy Should Men Choose in 2026?

For men with hypogonadism who want to father children, the choice between conventional testosterone replacement and enclomiphene is not a matter of preference — it is a matter of biology.

Oct 7, 2026
Share